|
Effect of Chemotherapy and Multimodality Therapy in Stage Ⅲ Patients with Bronchogenic Carcinoma <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
杨海山 教授、博士生导师
王田蔚 博士
赵永生 教授
吉林大学中日联谊医院放射线科，
吉林省长春市仙台大街2号，130031
ABSTRACT
Purpose: To compare short-term effect and side-effect of chemotherapy and multimodality therapy in stage Ⅲ patients with bronchogenic carcinoma.
Material and methods: 148 cases of stage Ⅲ lung cancer were divided into 2 groups. 64 cases were treated with BAI and chemotherapy in turn, so called multimodality therapy (group A), and 84 cases were treated with chemotherapy alone (group B). All patients were followed up with X ray plain film, CT, DSA, ECG and routine test of blood.
Results: Entire response rate reached 70.3% in group A and reached 32.2% in group B, showing significant difference (P<0.05). The symptom relief rate of group A was higher than group B (such as dyspnoea, pain, and atelectasis). Compare to group B, follow-up also showed low-toxicity in group A. Short-term effect was significantly associated with loss of body weight, stage, and administration (sex, age, and type showed no relations with short-term effect). The survival rate after 1 year of group A was superior to group B for NSCLC. And, that of group B was superior to group A for SCLC. Single factors Cox regression analysis shows survival time was significantly associated with stage, and loss of body weight. Multi-factors Cox regression analysis shows survival time was significantly associated with stage, and loss of body weight, and administration.
Conclusion: The improvement of entire response rate, relief rate, and survival rate in less toxicity was significant with BAI combination chemotherapy to that of chemotherapy alone ( follow-up 12-34moths ). The short-term effect of BAI combination chemotherapy was superior to chemotherapy alone for stage Ⅲ patients with NSCLC. Compare to chemotherapy alone, BAI combination chemotherapy showed higher entire response rate and relief rate but lower survival rate for stage Ⅲ patients with SCLC. Multi-factors Cox regression analysis shows survival time was significantly associated with stage, and loss of body weight, and administration.
Key word: Bronchogenic carcinoma; Bronchial artery infusion (BAI) |
